Corium International Inc (NASDAQ:CORI) VP Parminder Singh sold 3,133 shares of the business’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ:CORI traded up $0.24 during mid-day trading on Friday, reaching $8.93. The stock had a trading volume of 241,602 shares, compared to its average volume of 265,950. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $313.50 million, a P/E ratio of -5.45 and a beta of 1.45. Corium International Inc has a 1 year low of $7.17 and a 1 year high of $13.93.

Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $6.72 million. Corium International had a negative return on equity of 298.48% and a negative net margin of 155.21%. research analysts forecast that Corium International Inc will post -1.59 earnings per share for the current year.

CORI has been the topic of several research analyst reports. BidaskClub upgraded Corium International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 13th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a research report on Friday, May 18th. ValuEngine downgraded Corium International from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 17th. Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. Finally, HC Wainwright set a $14.00 price objective on Corium International and gave the company a “buy” rating in a research report on Tuesday, May 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Corium International has an average rating of “Buy” and a consensus price target of $12.80.

Large investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Corium International in the fourth quarter worth about $123,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Corium International in the first quarter worth about $167,000. Engineers Gate Manager LP purchased a new stake in shares of Corium International in the second quarter worth about $215,000. Goldman Sachs Group Inc. lifted its position in shares of Corium International by 126.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 18,416 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in shares of Corium International in the fourth quarter worth about $317,000. Institutional investors own 95.26% of the company’s stock.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Featured Article: Should I follow buy, hold and sell recommendations?

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.